- Home
- PRPL vs ESLA Comparison
PRPL vs ESLA Comparison
Compare PRPL & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRPL | ESLA |
|---|---|---|
| Founded | 2010 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.1M | 32.0M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PRPL | ESLA |
|---|---|---|
| Price | $3.27 | $0.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $0.65 | ★ $8.00 |
| AVG Volume (30 Days) | 24.8K | ★ 27.4K |
| Earning Date | 04-28-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 152.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $468,725,000.00 | N/A |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $6.68 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.28 | $0.59 |
| 52 Week High | $10.00 | $3.15 |
Technical Indicators
Market Signals| Indicator | PRPL | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 30.41 | 40.28 |
| Support Level | $0.51 | N/A |
| Resistance Level | $10.00 | $0.85 |
| Average True Range (ATR) | 0.29 | 0.07 |
| MACD | -0.21 | -0.00 |
| Stochastic Oscillator | 0.80 | 45.24 |
Price Performance
Historical ComparisonAbout PRPL Purple Innovation Inc.
Purple Innovation Inc designs and manufactures sleep products. Using its GelFlex Grid technology, the company designs, manufactures, and offers branded comfort sleep products, including mattresses, pillows, cushions, mattress protectors, bases, sheets, and others. It markets and sells these products through direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.